semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Prostatitis Pelvic Pain Male subjects aged 18 and older. 2. Male subjects with at least 3 months of symptoms of CP/CPPS who are refractory to other therapies 3. Subjects with a minimum score of 15 on the CPSI. 4. Male subjects must give written informed consent. 5. Male subjects must be willing an able to comply with the most recent version of the FDA-mandated S.T.E.P.S.â Program to He understands and can reliably carry out all instructions He is capable of complying with the mandatory contraceptive measures that are appropriate for male patient registration, and patient surveys as described in the S.T.E.P.S.â program He has received both oral and written warning of the hazards of taking thalidomide and exposing a fetus to the drug He has received both oral and written warning of the risk of possible contraception failure and of the presence of thalidomide in semen. He has been instructed that he must always use a late condom during any sexual contact with a woman of childbearing potential, even if he has undergone a successful vasectomy He acknowledges in writing his understanding of these warning and of the need to use a latex condom during any sexual contact with women of childbearing potential, even if he has undergone a successful vasectomy He agrees NOT to be a sperm or blood donor while being treated with thalidomide -  Subjects who are female. 2. Subjects with a documented positive urine culture (>100,000 CFU/mL) within the past six months 3. Subjects with duration of symptoms less than three months 4. Subjects with active genital infections 5. Subjects with prior urologic surgeries 6. Subjects with known active or prior genitourinary cancers including renal, ureteral, bladder or prostate 7. Subjects having received prior radiation to the abdominal or pelvic area 8. Subjects with known bladder or ureteral calculi 9. Subjects unable to complete a voiding diary 10. Subjects diagnosed with neuropathy 11. Subjects with neutropenia 12. Subjects with a history of deep venous thrombosis, pulmonary embolism, or hypercoagulable state 13. Any patient who is not willing to comply with the most recent version of the FDA-mandated S.T.E.P.Sâ program 14. Subjects with orthostatic hypotension 15. Subjects with known malignancies in the last 2 years
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Alzheimer's Disease Mild Cognitive Impairment Healthy for patients with dementia Patients: clinical diagnosis of AD or mild cognitive impairment primary language German  for healthy subjects and patients with dementia/MCI Known allergy to levodopa or tetrazine History of medication/drug abuse Acute nicotine withdrawal or > 15 cigarettes per day > 6 cups/glasses of coffee, caffeine drinks or energy drinks per day > 50 grams of alcohol per day Severe hypertonia (systole >160 mm Hg) Severe arteriosclerosis Diabetes, asthma, or glaucoma Severe hearing disability
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-80.0,  Parkinson's Disease Advanced Parkinson's disease (Hoehn & Yahr II-IV) Age of 30 to 80 years Levodopa-induced dyskinesias of at least 25% of the waking day and with moderate disability Stable dosage of antiparkinson medication and/or stable deep brain stimulation parameters for at least 4 week prior Written informed consent  Atypical parkinsonian syndromes Treatment with antipsychotics Epilepsia or seizure in the history Deep brain stimulation other than DBS in STN Pregnant or lactating women Severe dementia
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Parkinson's Disease Informed consent 2. 30 yrs or older 3. Diagnosis of PD (2 or more of bradykinesia; rest tremor, rigidity) 4. Adequate contraceptive measures (females)  Malignancy within last 2 years 2. Pregnancy & breast-feeding 3. Treatment with any anti-PD drugs within 30 days of enrolment 4. Prior treatment with anti-PD medication exceeding 42 days in total 5. Medication-induced PD/PD not of idiopathic origin 6. CoQ10/idebenone doses of 300mg/day or higher within 120 days, >25mg/day within 7 days of enrolment 7. Methylphenidate HCl, neuroleptics, reserpine, amphetamines, selegeline or MAOIs within 6 months of enrolment 8. CNS medications at unstable doses within 60 days of enrolment 9. Dietary supplements > 5 x RDI 10. Hypersensitivity to CoQ10, idebenone or any components of the study drug 11. Unable to swallow 12. Diseases with features of PD 13. Seizure(s) within 12 months prior to enrolment 14. UPDRS tremor score of 4 15. Hamilton Depression Rating Scale score > 10 16. History of stroke 17. Requirement for dopaminergic drugs 18. Modified Hoehn & Yahr score > 2.5 19. History of brain surgery for Parkinson's disease 20. History of structural brain disease / congenital brain abnormality 21. History of ECT 22. Any other clinically significant medical or psychiatric condition or lab abnormality 23. Enrolment in any other pharmacological study within 30 days of enrolment
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Parkinson's Disease Idiopathic PD treated with levodopa and experiencing motor fluctuations At least 21 years of age Male or female  Cardiovascular disease, psychosis, extreme anxiety, dementia and other unstable medical conditions
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Parkinson's Disease Men or Women between 18 and 80 years Patient has idiopathic Parkinson's Disease according to Brain Bank criteria. Reference Hughes A J, Daniel S E, Kilford L, Lees A J, Accuracy of Clinical Diagnosis of Idiopathic Parkinson's disease; A clinical Pathological study of 100 cases, JNNP 1992, 55(3): 181 Patient is on stable doses of anti-Parkinson's disease medication, which are not expected to change during the study period Patient is taking levodopa and/or dopamine agonist treatment Patient (assisted by a carer where appropriate) is able to take their medication using the MEMS (electronic monitoring) containers Patients using a dosette box or similar device for their medication are willing to use the MEMS containers for their PD medication The investigator judges that the patient's care and symptom control will not be adversely affected by entering the study and using the MEMS device  Patient is taking anti-Parkinson's disease therapy intermittently or on "as required" basis (such as rescue therapy for off periods). Intermittent Domperidone is allowed Severe co-morbid condition such as severe heart, liver, or kidney disease or cancer diagnosis where the co-morbid condition is of greater health significance than the Parkinson's disease in terms of life expectancy and levels of care required Patient is expected to undergo hospital admission during the study period (such as elective surgery) Patient is on non standard drug treatment / combination therapy. This would e.g. a combination of 2 different oral dopamine agonists, doses of dopamine agonist taken at higher than recommended for routine practice New antiparkinson treatment is being introduced at the time of recruitment or during the one month monitoring period Patient is taking only adjunct therapy (eg. Selegiline, Amantadine, anticholinergic therapy) Patient is taking part in a clinical trial
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-70.0,  Parkinson's Disease Parkinson Disease Dyskinesias Must be on 600mg or less of levodopa therapy for two years or less Must be on a stable dose of levodopa therapy for at least 4 weeks prior to screening  Current or past history of Dyskinesia State of dementia or have a MMSE score < 26 at screening
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prostate Cancer Patients with histologically confirmed diagnosis of prostate cancer who have not yet developed bone metastases Prostate cancer patients with a rise in PSA under hormone therapy. PSA Patients who have undergone prostatectomy: any rise in PSA or Patients without prostatectomy: 2 consecutive rises in PSA levels relative to a previous reference value, separated by one month. The first measurement must occur one month after the reference value and must be above the reference value. The second confirmatory measurement taken one month after the first measurement must be greater than the first measurement Previous chemotherapy or radiotherapy must have been performed ≥ 8 weeks prior to study entry Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (patients that spend less than 50% of time in bed during the day) Adequate liver function serum total bilirubin concentration less than 1.5 x upper limit of normal value Age: ≥ 18 years Patient has given written informed consent prior to any study-specific procedures. Patients with psychiatric or addictive disorders which prevent them from giving their informed consent must not enter the study  Prior treatment with a bisphosphonate Abnormal renal function as evidenced by a calculated creatinine clearance < 30 ml/minute Corrected (adjusted for serum albumin) serum calcium concentration < 8.0 mg/dl (2.00 mmol/L) or ≥ 12.0 mg/dl (3.00 mmol/L) Patients with clinically symptomatic brain metastases History of diseases with influence on bone metabolism such as Paget's disease and primary hyperparathyroidism Severe physical or psychological concomitant diseases that might impair compliance with the provisions of the study protocol or that might impair the assessment of drug or patient safety, e.g. clinically significant ascites, cardiac failure, NYHA III or IV, clinically relevant pathologic findings in ECG Known hypersensitivity to zoledronic acid or other bisphosphonates Use of other investigational drugs 30 days prior to the date of randomization Known history or present abuse of alcohol or drugs Subjects who, in the opinion of the investigator, are unlikely to cooperate fully during the study
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Hypertension ACEi or ARB naive or not taking ACEi or ARB concurrently for at least one month before the run-in period Be able to carry out his or her own daily activity Be at least 50 years old at in the study Be diagnosed with mild to moderate hypertension, treated or untreated Literate Not taking any cognitive-enhanced agent at baseline Present with a memory complain ( spontaneous or informed by caregiver)  Congestive heart failure with NYHA class >2 Renal failure or renal insufficiency with serum creatinine >1.4mg/dl chronic severe liver disease with abnormal GPT and GOT >2 times of upper normal limits Diagnosed with major depression when entering the study Foreign language as his or her mother tongue so that the test results will not be reliable History of stroke or transient ischemic attack (stroke is defined as focal neurological sign progressing stepwise) Hypersensitive to the active ingredient and any other component of losartan potassium and indapamide tablets Major hearing loss/deafness and/or major visual impairment/blindness preventing from performing the tests Myocardial infarction within the past 6 months Single functioning kidney
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cardiovascular Diseases Patient is male or female older 18 years of age. 2. Patients with a diagnosis of primary hypercholesterolemia and who are defined as being "high risk" (10-year risk of coronary artery disease greater than 20 % based on the Framingham model and history of cardiovascular disease or) 3. Patients who have not reached their recommended LDL-C target levels of 2.5 mmol/L while on a statin alone. 4. According to the judgment of the treating physician patient enrollment is in the best interest of the patient. 5. Patient agrees to participate and signs an informed consent allowing follow up and sharing of patient related data  Individuals with poor mental function, drug or substance abuse, or individuals with unstable psychiatric illnesses, which, in the opinion of the investigator, may interfere with optimal participation in the observational study. Alcoholic substance abuse would be defined as a patient with alcohol consumption > 14 drink per week. (A drink is: a can of beer, glass of wine, or single measure of spirits.) 2. Patients who have been treated with any investigational drug within 30 days prior to Visit 1. (If <30 days, contact the clinical monitor for a case-by-case evaluation.) 3. Patients with clinically significant concomitant illnesses of liver, muscle or kidney abnormalities
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypertension Diabetes Hypercholesterolemia Vasculitis Coronary Heart Diseases All inpatients in a hospital environment  Inability to give an informed consent
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Bradycardia Slow Heart Beat Subject has, or is at risk of having, a heart beat that is too slow and his/her doctor has determined he/she needs a pacemaker Subject available for follow-up at study center for length of study Subject able and willing to undergo elective MRI scanning without sedation  Subject has, or is at risk of having, a heart beat that is too fast and his/her doctor has determined he/she needs an implantable cardioverter defibrillator (ICD) Subject needs or will need another MRI-scan, other than those required by the study, during the required study follow-up period Pregnant women, or women of child bearing potential who are not on a reliable form of birth control Subject with required by local law Subject who intends to participate in another clinical study during this clinical study
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson's Disease Patients on anti-parkinson medication who Have been on monotherapy for a prolonged period, or Use anti-parkinson medications intermittently, or Do not have the expected change in medication over time in keeping with degenerative Parkinson's disease  Patients on anti-parkinson medication for reasons other than Parkinson's disease Patients with significant co-morbidity (end stage liver, cardiac or renal disease)